Johnson & Johnson (NYSE:JNJ) Stock Holdings Trimmed by Burkett Financial Services LLC

Burkett Financial Services LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 13.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 3,182 shares of the company’s stock after selling 512 shares during the period. Burkett Financial Services LLC’s holdings in Johnson & Johnson were worth $460,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Highline Wealth Partners LLC bought a new position in shares of Johnson & Johnson during the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares during the period. Activest Wealth Management acquired a new position in shares of Johnson & Johnson during the third quarter worth approximately $40,000. Finally, Morton Brown Family Wealth LLC boosted its position in shares of Johnson & Johnson by 400.0% during the third quarter. Morton Brown Family Wealth LLC now owns 250 shares of the company’s stock worth $41,000 after buying an additional 200 shares during the period. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $0.26 during midday trading on Monday, hitting $144.45. The company’s stock had a trading volume of 2,822,416 shares, compared to its average volume of 4,848,423. The stock has a market capitalization of $347.78 billion, a price-to-earnings ratio of 20.90, a PEG ratio of 2.52 and a beta of 0.51. The stock’s 50 day simple moving average is $151.40 and its 200 day simple moving average is $156.28. Johnson & Johnson has a fifty-two week low of $142.75 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the firm earned $2.66 EPS. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, research analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Wolfe Research started coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Citigroup cut their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.